198 related articles for article (PubMed ID: 33196965)
1. Quantitative CEST and MT at 1.5T for monitoring treatment response in glioblastoma: early and late tumor progression during chemoradiation.
Chan RW; Chen H; Myrehaug S; Atenafu EG; Stanisz GJ; Stewart J; Maralani PJ; Chan AKM; Daghighi S; Ruschin M; Das S; Perry J; Czarnota GJ; Sahgal A; Lau AZ
J Neurooncol; 2021 Jan; 151(2):267-278. PubMed ID: 33196965
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Glioblastoma Response to Therapy With Chemical Exchange Saturation Transfer.
Mehrabian H; Myrehaug S; Soliman H; Sahgal A; Stanisz GJ
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):713-723. PubMed ID: 29893279
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma (GBM) effects on quantitative MRI of contralateral normal appearing white matter.
Mehrabian H; Lam WW; Myrehaug S; Sahgal A; Stanisz GJ
J Neurooncol; 2018 Aug; 139(1):97-106. PubMed ID: 29594656
[TBL] [Abstract][Full Text] [Related]
4. Quantitating Interfraction Target Dynamics During Concurrent Chemoradiation for Glioblastoma: A Prospective Serial Imaging Study.
Stewart J; Sahgal A; Lee Y; Soliman H; Tseng CL; Detsky J; Husain Z; Ho L; Das S; Maralani PJ; Lipsman N; Stanisz G; Perry J; Chen H; Atenafu EG; Campbell M; Lau AZ; Ruschin M; Myrehaug S
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):736-746. PubMed ID: 33068687
[TBL] [Abstract][Full Text] [Related]
5. pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma.
Yao J; Tan CHP; Schlossman J; Chakhoyan A; Raymond C; Pope WB; Salamon N; Lai A; Ji M; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2019 May; 142(3):587-595. PubMed ID: 30806888
[TBL] [Abstract][Full Text] [Related]
6. Intravoxel incoherent motion (IVIM) modeling of diffusion MRI during chemoradiation predicts therapeutic response in IDH wildtype glioblastoma.
Jabehdar Maralani P; Myrehaug S; Mehrabian H; Chan AKM; Wintermark M; Heyn C; Conklin J; Ellingson BM; Rahimi S; Lau AZ; Tseng CL; Soliman H; Detsky J; Daghighi S; Keith J; Munoz DG; Das S; Atenafu EG; Lipsman N; Perry J; Stanisz G; Sahgal A
Radiother Oncol; 2021 Mar; 156():258-265. PubMed ID: 33418005
[TBL] [Abstract][Full Text] [Related]
7. Chemical Exchange Saturation Transfer MRI for Differentiating Radiation Necrosis From Tumor Progression in Brain Metastasis-Application in a Clinical Setting.
Mehrabian H; Chan RW; Sahgal A; Chen H; Theriault A; Lam WW; Myrehaug S; Tseng CL; Husain Z; Detsky J; Soliman H; Stanisz GJ
J Magn Reson Imaging; 2023 Jun; 57(6):1713-1725. PubMed ID: 36219521
[TBL] [Abstract][Full Text] [Related]
8. Relaxation-compensated CEST-MRI of the human brain at 7T: Unbiased insight into NOE and amide signal changes in human glioblastoma.
Zaiss M; Windschuh J; Paech D; Meissner JE; Burth S; Schmitt B; Kickingereder P; Wiestler B; Wick W; Bendszus M; Schlemmer HP; Ladd ME; Bachert P; Radbruch A
Neuroimage; 2015 May; 112():180-188. PubMed ID: 25727379
[TBL] [Abstract][Full Text] [Related]
9. Identification of a candidate biomarker from perfusion MRI to anticipate glioblastoma progression after chemoradiation.
Khalifa J; Tensaouti F; Chaltiel L; Lotterie JA; Catalaa I; Sunyach MP; Ibarrola D; Noël G; Truc G; Walker P; Magné N; Charissoux M; Ken S; Peran P; Berry I; Moyal EC; Laprie A
Eur Radiol; 2016 Nov; 26(11):4194-4203. PubMed ID: 26843012
[TBL] [Abstract][Full Text] [Related]
10. Direct radiofrequency saturation corrected amide proton transfer tumor MRI at 3T.
Wu Y; Chen Y; Zhao Y; Yang S; Zhao J; Zhou J; Chen Z; Sun PZ; Zheng H
Magn Reson Med; 2019 Apr; 81(4):2710-2719. PubMed ID: 30390326
[TBL] [Abstract][Full Text] [Related]
11. Amide proton transfer imaging of glioblastoma, neuroblastoma, and breast cancer cells on a 11.7 T magnetic resonance imaging system.
Tanoue M; Saito S; Takahashi Y; Araki R; Hashido T; Kioka H; Sakata Y; Yoshioka Y
Magn Reson Imaging; 2019 Oct; 62():181-190. PubMed ID: 31302222
[TBL] [Abstract][Full Text] [Related]
12. Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma.
Müller A; Jurcoane A; Kebir S; Ditter P; Schrader F; Herrlinger U; Tzaridis T; Mädler B; Schild HH; Glas M; Hattingen E
Cancer Med; 2017 Jan; 6(1):89-99. PubMed ID: 27891815
[TBL] [Abstract][Full Text] [Related]
13. Nuclear overhauser enhancement mediated chemical exchange saturation transfer imaging at 7 Tesla in glioblastoma patients.
Paech D; Zaiss M; Meissner JE; Windschuh J; Wiestler B; Bachert P; Neumann JO; Kickingereder P; Schlemmer HP; Wick W; Nagel AM; Heiland S; Ladd ME; Bendszus M; Radbruch A
PLoS One; 2014; 9(8):e104181. PubMed ID: 25111650
[TBL] [Abstract][Full Text] [Related]
14. Robust texture features for response monitoring of glioblastoma multiforme on T1-weighted and T2-FLAIR MR images: a preliminary investigation in terms of identification and segmentation.
Assefa D; Keller H; Ménard C; Laperriere N; Ferrari RJ; Yeung I
Med Phys; 2010 Apr; 37(4):1722-36. PubMed ID: 20443493
[TBL] [Abstract][Full Text] [Related]
15. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
Wen Q; Jalilian L; Lupo JM; Molinaro AM; Chang SM; Clarke J; Prados M; Nelson SJ
J Neurooncol; 2015 Jan; 121(2):331-9. PubMed ID: 25351579
[TBL] [Abstract][Full Text] [Related]
16. Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.
Ellingson BM; Abrey LE; Garcia J; Chinot O; Wick W; Saran F; Nishikawa R; Henriksson R; Mason WP; Harris RJ; Leu K; Woodworth DC; Mehta A; Raymond C; Chakhoyan A; Pope WB; Cloughesy TF
Neuro Oncol; 2018 Oct; 20(11):1525-1535. PubMed ID: 29897562
[TBL] [Abstract][Full Text] [Related]
17. Early response assessment of glioma patients to definitive chemoradiotherapy using chemical exchange saturation transfer imaging at 7 T.
Meissner JE; Korzowski A; Regnery S; Goerke S; Breitling J; Floca RO; Debus J; Schlemmer HP; Ladd ME; Bachert P; Adeberg S; Paech D
J Magn Reson Imaging; 2019 Oct; 50(4):1268-1277. PubMed ID: 30864193
[TBL] [Abstract][Full Text] [Related]
18. Volumetric and MGMT parameters in glioblastoma patients: survival analysis.
Iliadis G; Kotoula V; Chatzisotiriou A; Televantou D; Eleftheraki AG; Lambaki S; Misailidou D; Selviaridis P; Fountzilas G
BMC Cancer; 2012 Jan; 12():3. PubMed ID: 22214427
[TBL] [Abstract][Full Text] [Related]
19. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
[TBL] [Abstract][Full Text] [Related]
20. Semi-solid MT and APTw CEST-MRI predict clinical outcome of patients with glioma early after radiotherapy.
Kroh F; von Knebel Doeberitz N; Breitling J; Maksimovic S; König L; Adeberg S; Scherer M; Unterberg A; Bendszus M; Wick W; Bachert P; Debus J; Ladd ME; Schlemmer HP; Korzowski A; Goerke S; Paech D
Magn Reson Med; 2023 Oct; 90(4):1569-1581. PubMed ID: 37317562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
